{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:47:07Z","timestamp":1780613227450,"version":"3.54.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Autosomal dominant polycystic kidney disease causes chronic kidney disease and end-stage renal disease. Mechanisms include cyst production, multiplication, and enlargement leading to increased kidney size, and ultimately kidney failure. Although there is no known cure, NPs are uniquely positioned to help patients manage their symptoms and delay onset of kidney failure and need for dialysis.<\/jats:p>","DOI":"10.1097\/01.npr.0000718496.52494.30","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T17:01:25Z","timestamp":1603299685000},"page":"41-47","source":"Crossref","is-referenced-by-count":1,"title":["Recognizing and treating autosomal dominant polycystic kidney disease"],"prefix":"10.1097","volume":"45","author":[{"given":"Chigozie G.","family":"Uko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-20230929","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117693355","article-title":"Total kidney volume as a biomarker of disease progression in autosomal dominant polycystic kidney disease","volume":"4","author":"Tangri","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"R9-20230929","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/TCRM.S196244","article-title":"Autosomal dominant polycystic kidney disease: updated perspectives","volume":"15","author":"Rastogi","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"R10-20230929","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"R11-20230929","doi-asserted-by":"crossref","DOI":"10.15586\/codon.pkd.2015.ch3","article-title":"Treatment and management of autosomal dominant polycystic kidney disease","author":"Helal","year":"2015","journal-title":"Polycystic Kidney Disease"},{"issue":"10174","key":"R12-20230929","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"R13-20230929","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ajkd.2017.11.015","article-title":"The value of genetic testing in polycystic kidney diseases illustrated by a family with PKD2 and COL4A1 mutations","volume":"72","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R15-20230929","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2054358117695784","article-title":"Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a Canadian expert consensus","volume":"4","author":"Soroka","year":"2017","journal-title":"Can J Kidney Health Dis"},{"issue":"10","key":"R17-20230929","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"R18-20230929","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"R19-20230929","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"24","key":"R21-20230929","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"R22-20230929","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"R23-20230929","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"}],"container-title":["The Nurse Practitioner"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NPR.0000718496.52494.30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T20:08:47Z","timestamp":1696018127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NPR.0000718496.52494.30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/01.npr.0000718496.52494.30","relation":{},"ISSN":["0361-1817"],"issn-type":[{"value":"0361-1817","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}